Jim Simons
FULC icon

Jim Simons’s Fulcrum Therapeutics FULC Stock Holding History

Jim Simons’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$104K Sell
13,600
-3,800
-22% -$35.2K ﹤0.01% 3025
2025
Q4 		$197K Sell
17,400
-230,800
-93% -$2.35M ﹤0.01% 2888
2025
Q3 		$2.28M Buy
248,200
+169,700
+216% +$1.23M ﹤0.01% 1983
2025
Q2 		$540K Sell
78,500
-322,600
-80% -$1.73M ﹤0.01% 2793
2025
Q1 		$1.16M Buy
+401,100
New +$1.47M ﹤0.01% 2324
2024
Q3 		– Sell
-13,257
Closed -$82.2K – 3652
2024
Q2 		$82.2K Buy
+13,257
New +$100K ﹤0.01% 3219
2023
Q4 		– Sell
-52,734
Closed -$234K – 3846
2023
Q3 		$234K Sell
52,734
-292,076
-85% -$1.28M ﹤0.01% 3037
2023
Q2 		$1.14M Sell
344,810
-45,290
-12% -$133K ﹤0.01% 2390
2023
Q1 		$1.11M Buy
+390,100
New +$3.5M ﹤0.01% 2409
2022
Q3 		– Sell
-68,000
Closed -$333K – 4147
2022
Q2 		$333K Buy
+68,000
New +$665K ﹤0.01% 3396
2021
Q4 		– Sell
-133,900
Closed -$3.78M – 4004
2021
Q3 		$3.78M Buy
+133,900
New +$2.54M ﹤0.01% 1631

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Jim Simons's FULC Position: Q1 2026 in Review

Jim Simons reduced its Fulcrum Therapeutics (FULC) stake by 22% in Q1 2026, selling an estimated $35.2K and leaving 13,600 shares worth $104K. The position accounts for ﹤0.01% of the portfolio, ranked #3025.

Jim Simons first reported a position in FULC in Q3 2021 and has held it in 11 quarters since. The position peaked at $3.78M in Q3 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Jim Simons held 13,600 shares of Fulcrum Therapeutics worth $104K as of Q1 2026.
  • Jim Simons sold 3,800 Fulcrum Therapeutics shares in Q1 2026, an estimated $35.2K.
  • Fulcrum Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q1 2026, its #3025 holding.
  • Jim Simons first reported a position in Fulcrum Therapeutics in Q3 2021 and has held it in 11 quarters since.
  • Jim Simons's Fulcrum Therapeutics position peaked at $3.78M in Q3 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.